Linalool / Casp3 Cancer Research Results

LIN, Linalool: Click to Expand ⟱
Features:

Linalool — Linalool is a naturally occurring acyclic monoterpene tertiary alcohol and volatile terpene found in many essential oils, including lavender, coriander, basil, rosewood, and citrus-associated oils. It is formally classified as a small-molecule phytochemical / monoterpenoid fragrance and flavor compound, commonly abbreviated as LIN or Lin. It exists as enantiomers with different odor profiles and biological handling. In oncology research, linalool is best treated as a preclinical bioactive terpene with in-vitro and limited animal-model anticancer signals, not as a clinically validated anticancer therapy.

Primary mechanisms (ranked):

  1. Induction of apoptosis through intrinsic mitochondrial and extrinsic death-receptor pathways, with caspase activation and reduced proliferation markers.
  2. Cell-cycle arrest and suppression of proliferative signaling, including Ras/MAPK and PI3K/Akt/mTOR-associated axes in selected cancer models.
  3. Oxidative stress-mediated cancer-cell killing, including cancer-selective hydroxyl radical generation in colon cancer models.
  4. Autophagy modulation, usually linked to Akt/mTOR suppression, but interpretation is model-dependent and not yet clinically established.
  5. Anti-migration / anti-metastatic effects in lung cancer cell models at high in-vitro concentrations.
  6. Anti-inflammatory and neuroactive effects, relevant mainly to symptom-support or non-cancer contexts rather than direct tumor cytotoxicity.

Bioavailability / PK relevance: Linalool is volatile and lipophilic, with systemic exposure possible after oral, inhaled, and transdermal routes, but therapeutic plasma levels for anticancer effects remain uncertain. Human oral PK methods have been developed, and inhalation/transdermal studies support absorption, but most anticancer experiments use concentrations that are difficult to map directly to achievable human exposure.

In-vitro vs systemic exposure relevance: Many anticancer studies use high micromolar to millimolar linalool concentrations, especially in lung, liver, leukemia, prostate, and colon cancer cell models. These levels may exceed realistic systemic exposure from food, fragrance, aromatherapy, or ordinary essential-oil use. Direct anticancer interpretation should therefore be concentration-constrained.

Clinical evidence status: Preclinical. Linalool itself has no established cancer-treatment indication. Human studies involving linalool-rich essential oils or aromatherapy are mainly supportive-care studies for anxiety, sleep, pain, or procedural distress, not tumor-response trials. Regulatory status is primarily as a flavor/fragrance substance, not as an approved oncology drug.

Linalool Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Intrinsic and extrinsic apoptosis ↑ caspase signaling; ↑ apoptotic fraction; ↓ Ki-67 and PCNA in prostate xenograft model Less defined; cytotoxic selectivity is model-dependent G Programmed cancer-cell death Core anticancer mechanism across several models; strongest translational signal is still preclinical.
2 Cell-cycle arrest ↑ G0/G1 or G2/M arrest depending on model; ↓ proliferation Context-dependent G Growth suppression Observed in leukemia, cervical, liver, and other cancer-cell studies; phase specificity varies by cell type.
3 PI3K Akt mTOR signaling ↓ Akt/mTOR-associated survival signaling; ↑ apoptosis/autophagy linkage Not well established R/G Survival-pathway inhibition Mechanistically plausible and reported in HepG2 and other models; one colorectal paper on Akt/mTOR and JAK2/STAT3 was later retracted and should not be used as support.
4 Ras MAPK signaling ↓ Ras/MAPK-associated proliferation signaling in HepG2 model Context-dependent R/G Reduced proliferative signaling Important in liver cancer-cell data but not yet a universal linalool mechanism.
5 Cancer-selective hydroxyl radical generation ↑ hydroxyl radicals; ↑ apoptosis in colon cancer models Proposed relative selectivity, but exposure margin uncertain R/G Oxidative cytotoxicity Useful ROS-related mechanism; should be listed as pro-oxidant cancer stress rather than antioxidant activity.
6 Mitochondrial stress ↑ mitochondrial apoptotic signaling; altered Bcl-2 family / caspase cascade in selected models Potential normal-cell toxicity at high concentration R/G Apoptosis amplification Best treated as part of apoptosis rather than a separate mitochondrial-targeted drug mechanism.
7 Autophagy modulation ↑ autophagy markers or autophagy-apoptosis interaction in some models Not well defined G Context-dependent death or stress response Autophagy may be pro-death or adaptive depending on model; avoid over-ranking unless specific cancer data support it.
8 Migration and metastasis behavior ↓ wound closure / migration in A549 cells at high concentration Not established G Reduced motility Potential anti-metastatic signal, but mainly high-concentration in-vitro evidence.
9 Inflammatory signaling ↓ inflammatory mediators in non-cancer inflammatory models; cancer relevance indirect May reduce inflammatory tone in some normal-tissue contexts R/G Supportive or microenvironmental modulation Relevant to aromatherapy/supportive-care context more than direct tumor killing.
10 Clinical Translation Constraint High in-vitro concentrations may not be clinically achievable Oxidized linalool can cause contact allergy; essential-oil exposures vary widely G Limits therapeutic extrapolation Major constraints are volatility, low water solubility, formulation dependence, variable systemic exposure, and lack of oncology efficacy trials.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
6483- LIN,    Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma
- in-vitro, Ovarian, A2780S
Apoptosis↑, ROS↑, MMP↓, Casp3↑, TumW↓, ChemoSen↑, EPR↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp3↑, 1,  

Angiogenesis & Vasculature ⓘ

EPR↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Functional Outcomes ⓘ

TumW↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:410  Target#:42  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page